Pulmonx Reports Q1 Revenue Decline, Improves Margins, Reaffirms 2026 Guidance
summarizeSummary
Pulmonx Corporation reported a 9% year-over-year revenue decrease in Q1 2026, but showed improved gross margins and reduced operating expenses, while reaffirming its full-year 2026 financial outlook.
check_boxKey Events
-
Q1 Revenue Decline
Worldwide revenue decreased 9% year-over-year to $20.6 million in the first quarter of 2026.
-
Operational Efficiency Improvements
Gross margin improved to 78% from 73% in the prior year, and operating expenses decreased by 6%.
-
International Growth Excluding China
International revenue grew 22% year-over-year when excluding the impact of sales into China.
-
Reaffirmed Full-Year Guidance
Pulmonx reiterated its full-year 2026 revenue, gross margin, and operating expense guidance.
auto_awesomeAnalysis
Despite a 9% year-over-year decline in worldwide revenue, Pulmonx demonstrated operational improvements with an increased gross margin and reduced operating expenses. The company also highlighted strong international revenue growth when excluding the impact of China, and reaffirmed its full-year 2026 guidance, suggesting management's confidence in future performance. This mixed report, coming as the stock trades near its 52-week low, could signal a potential stabilization point for investors.
At the time of this filing, LUNG was trading at $1.15 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $50.7M. The 52-week trading range was $1.13 to $5.46. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.